(Q58405284)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Results of a randomized controlled trial on statin use in dialysis patients had no influence on statin prescription (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

randomized controlled trial

8 February 2020

main subject

renal dialysis

0 references

1 reference

Ping Li

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Ngan N Lam

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Arsh K Jain

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Dan G Hackam

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Meaghan S Cuerden

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Cindy Y Huo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

William F Clark

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

language of work or name

English

0 references

publication date

23 September 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

1172-1179

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/ki.2009.323

8 February 2020

exact match

0 references

cites work

The randomized clinical trial: an unbeatable standard in clinical research?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Use of the statins in patients after acute myocardial infarction: does evidence change practice?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Prescriptions for Estrogen Replacement Therapy in Ontario Before and After Publication of the Women's Health Initiative Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

The number, quality, and coverage of randomized controlled trials in nephrology.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Study of Heart and Renal Protection (SHARP)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

The design of a prospective study of pravastatin in the elderly at risk (PROSPER)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.323

7 January 2021

Identifiers

DOI

10.1038/KI.2009.323

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19776719%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference